HLA-C and neoplasm: These neoantigen-loaded APCs subsequently migrate to the tumor-draining lymph node (TDLN), where the peptide-MHC is recognized by the T cell receptor (TCR), stimulated by corresponding co-stimulatory signals and cytokines.